Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

#4659

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Aim(s): Primary endpoint: the tumour (tu) growth rate (TGR) initially during follow-up without therapy & then during lanreotide therapy. Second aim to assess initially & during lanreotide therapy biochemical response with secretor tu by cyclic fractionated metoxycatecholamines evaluation in follow-up.

Materials and methods: Initially 20 pts from 37 screened all with confirmation of unresectable, advance PPGL, treated with lanreotide; 3 of them exclude due to metastatic disease, 17 subjects include in the study. Mean age of 45.3; sporadic/hereditary 4/13 subjects. Disease status & treatment response evaluated by clinical assessment; biochemical responses & TGR based on RECIST 1.1.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,